

Shiva Malek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6953827/publications.pdf>

Version: 2024-02-01

56
papers

5,804
citations

159358

30
h-index

168136

53
g-index

60
all docs

60
docs citations

60
times ranked

8356
citing authors

#	ARTICLE	IF	CITATIONS
1	RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. <i>Nature</i> , 2010, 464, 431-435.	13.7	1,451
2	The Crystal Structure of the I κ B α /NF- κ B Complex Reveals Mechanisms of NF- κ B Inactivation. <i>Cell</i> , 1998, 95, 759-770.	13.5	592
3	RAS-targeted therapies: is the undruggable drugged?. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 533-552.	21.5	569
4	Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5299-5304.	3.3	526
5	Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. <i>Nature</i> , 2013, 501, 232-236.	13.7	270
6	Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition. <i>Nature Chemical Biology</i> , 2016, 12, 779-786.	3.9	180
7	Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling. <i>Cancer Cell</i> , 2014, 26, 402-413.	7.7	173
8	Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2. <i>Cancer Cell</i> , 2016, 29, 477-493.	7.7	171
9	I κ B β , but Not I κ B α , Functions as a Classical Cytoplasmic Inhibitor of NF- κ B Dimers by Masking Both NF- κ B Nuclear Localization Sequences in Resting Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 45225-45235.	1.6	152
10	I κ B α Functions through Direct Contacts with the Nuclear Localization Signals and the DNA Binding Sequences of NF- κ B. <i>Journal of Biological Chemistry</i> , 1998, 273, 25427-25435.	1.6	148
11	Mechanism of κ B DNA binding by Rel/NF- κ B dimers. <i>Journal of Biological Chemistry</i> , 2000, 275, 24392-24399.	1.6	120
12	X-ray Crystal Structure of an I κ B α -NF- κ B p65 Homodimer Complex. <i>Journal of Biological Chemistry</i> , 2003, 278, 23094-23100.	1.6	107
13	Noncovalent Wild-type "Sparing Inhibitors of EGFR T790M. <i>Cancer Discovery</i> , 2013, 3, 168-181.	7.7	87
14	Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3186-3194.	1.0	72
15	Structure of G.cntdot.T.cntdot.A triplet in an intramolecular DNA triplex. <i>Biochemistry</i> , 1992, 31, 4838-4846.	1.2	71
16	Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 134-141.	3.6	66
17	ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. <i>Nature</i> , 2021, 594, 418-423.	13.7	64
18	Discovery of XL888: A novel tropane-derived small molecule inhibitor of HSP90. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5396-5404.	1.0	57

#	ARTICLE	IF	CITATIONS
19	Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10176-10191.	2.9	53
20	Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5533-5539.	1.0	52
21	Identification of Preferred Chemotherapeutics for Combining with a <i>CHK1</i> Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2285-2295.	1.9	52
22	Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors. <i>Cancer Cell</i> , 2018, 34, 611-625.e7.	7.7	51
23	Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 103-107.	1.3	43
24	Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 8877-8895.	2.9	43
25	4-Aminoindazolyl-dihydrofuro[3,4- d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 534-539.	1.0	42
26	Cell Active Hydroxylactam Inhibitors of Human Lactate Dehydrogenase with Oral Bioavailability in Mice. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 896-901.	1.3	41
27	Targeting the MAPK Pathway in RAS Mutant Cancers. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a031492.	2.9	41
28	RTK-Dependent Inducible Degradation of Mutant PI3K α Drives GDC-0077 (Inavolisib) Efficacy. <i>Cancer Discovery</i> , 2022, 12, 204-219.	7.7	40
29	Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3764-3771.	1.0	37
30	Combination Drug Scheduling Defines a "Window of Opportunity" for Chemopotential of Gemcitabine by an Orally Bioavailable, Selective Chk1 Inhibitor, GNE-900. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1968-1980.	1.9	34
31	Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 100-104.	1.3	29
32	Dimerization Induced by C-Terminal 14 α -3 Binding Is Sufficient for BRAF Kinase Activation. <i>Biochemistry</i> , 2020, 59, 3982-3992.	1.2	29
33	Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR). <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3090-3101.	2.9	28
34	Potent, Selective, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin Kinase Domain Exhibiting Single Agent Antiproliferative Activity. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10958-10971.	2.9	27
35	A hit to lead discovery of novel N-methylated imidazo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5097-5104.	1.0	26
36	Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways. <i>Cancer Discovery</i> , 2021, 11, 778-793.	7.7	26

#	ARTICLE	IF	CITATIONS
37	Potent, Selective, and Orally Bioavailable Inhibitors of Mammalian Target of Rapamycin (mTOR) Kinase Based on a Quaternary Substituted Dihydrofuropyrimidine. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3426-3435.	2.9	25
38	Emerging Trends in Cancer Drug Discovery—From Drugging the “Undruggable” to Overcoming Resistance. <i>Cancer Discovery</i> , 2021, 11, 815-821.	7.7	24
39	Optimization of 5-(2,6-dichlorophenyl)-3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 75-82.	1.0	18
40	CRAF dimerization with ARAF regulates KRAS-driven tumor growth. <i>Cell Reports</i> , 2022, 38, 110351.	2.9	18
41	Identification of 3,6-disubstituted dihydropyrones as inhibitors of human lactate dehydrogenase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5683-5687.	1.0	17
42	Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3 <i>H</i>)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3940-3955.	2.9	17
43	Preparation and Crystallization of Dynamic NF- κ B Complexes. <i>Journal of Biological Chemistry</i> , 2000, 275, 32800-32806.	1.6	16
44	Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9080-9093.	2.9	16
45	Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5704-5709.	1.0	14
46	Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5053-5074.	2.9	14
47	RAS-targeted therapies. <i>Nature Reviews Drug Discovery</i> , 2021, , .	21.5	14
48	The promise and peril of KRAS G12C inhibitors. <i>Cancer Cell</i> , 2021, 39, 1059-1061.	7.7	10
49	The RAS/MAPK Axis Gets Stressed Out. <i>Molecular Cell</i> , 2016, 64, 854-855.	4.5	7
50	Tissue-Specific Mutations in BRAF and EGFR Necessitate Unique Therapeutic Approaches. <i>Trends in Cancer</i> , 2016, 2, 699-701.	3.8	4
51	Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 791-797.	1.3	3
52	Partners in Crime: Clandestine Operations among RAS-RAF Accomplices in Promoting Tumorigenesis. <i>Molecular Cell</i> , 2019, 76, 853-855.	4.5	1
53	Biology, technology and a bit of serendipity: an interview with Shiva Malek. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	1
54	A Plate-Based Assay to Measure Cellular ERK Substrate Phosphorylation: Utility for Drug Discovery of the MAPK-Signaling Cascade. <i>Assay and Drug Development Technologies</i> , 2010, 8, 497-503.	0.6	0

#	ARTICLE	IF	CITATIONS
55	A BRAFâ€MEK complex reveals the molecular basis of oncogenic mutations. FASEB Journal, 2013, 27, 1031.11.	0.2	0
56	Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase. Bioorganic and Medicinal Chemistry Letters, 2022, 59, 128576.	1.0	0